| Kristin Lorraine Martin, MD | |
|
100 N Academy Ave, Danville, PA 17822-6202 | |
| (570) 271-6298 | |
| (570) 271-5841 |
| Full Name | Kristin Lorraine Martin |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 9 Years |
| Location | 100 N Academy Ave, Danville, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033590104 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johns Hopkins Bayview Medical Center | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Johns Hopkins University | 8921903147 | 2692 |
News Archive
People who exhibit a resistance to aspirin may be more likely to have more severe strokes than people who still respond to the drug, according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015.
Omnicare, Inc. today announced that it intends to offer $400 million aggregate principal amount of senior subordinated notes due 2020, pursuant to a preliminary prospectus supplement to be filed with the Securities and Exchange Commission under the Company's shelf registration statement.
This post in the Center for Strategic and International Studies' "Smart Global Health" blog examines drug-resistant tuberculosis (TB), stating, "[S]ince the recent outbreak of the so-called totally drug-resistant tuberculosis (TDR-TB) in India, TB has a new face."
Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.
› Verified 8 days ago
| Entity Name | Baltimore Medical System, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700882503 PECOS PAC ID: 5395653455 Enrollment ID: O20031121000651 |
News Archive
People who exhibit a resistance to aspirin may be more likely to have more severe strokes than people who still respond to the drug, according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015.
Omnicare, Inc. today announced that it intends to offer $400 million aggregate principal amount of senior subordinated notes due 2020, pursuant to a preliminary prospectus supplement to be filed with the Securities and Exchange Commission under the Company's shelf registration statement.
This post in the Center for Strategic and International Studies' "Smart Global Health" blog examines drug-resistant tuberculosis (TB), stating, "[S]ince the recent outbreak of the so-called totally drug-resistant tuberculosis (TDR-TB) in India, TB has a new face."
Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.
› Verified 8 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
People who exhibit a resistance to aspirin may be more likely to have more severe strokes than people who still respond to the drug, according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015.
Omnicare, Inc. today announced that it intends to offer $400 million aggregate principal amount of senior subordinated notes due 2020, pursuant to a preliminary prospectus supplement to be filed with the Securities and Exchange Commission under the Company's shelf registration statement.
This post in the Center for Strategic and International Studies' "Smart Global Health" blog examines drug-resistant tuberculosis (TB), stating, "[S]ince the recent outbreak of the so-called totally drug-resistant tuberculosis (TDR-TB) in India, TB has a new face."
Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristin Lorraine Martin, MD 6201 Greenleigh Ave, Middle River, MD 21220-2004 Ph: (410) 933-6423 | Kristin Lorraine Martin, MD 100 N Academy Ave, Danville, PA 17822-6202 Ph: (570) 271-6298 |
News Archive
People who exhibit a resistance to aspirin may be more likely to have more severe strokes than people who still respond to the drug, according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015.
Omnicare, Inc. today announced that it intends to offer $400 million aggregate principal amount of senior subordinated notes due 2020, pursuant to a preliminary prospectus supplement to be filed with the Securities and Exchange Commission under the Company's shelf registration statement.
This post in the Center for Strategic and International Studies' "Smart Global Health" blog examines drug-resistant tuberculosis (TB), stating, "[S]ince the recent outbreak of the so-called totally drug-resistant tuberculosis (TDR-TB) in India, TB has a new face."
Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.
› Verified 8 days ago
Dr. Latif L. Awad, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6298 | |
Dr. Diane De Lisi Timms, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6298 Fax: 570-271-5841 | |
Dr. Brytanie Nicole Marshall, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 100 North Academy Ave., Danville, PA 17822 Phone: 570-271-6298 Fax: 570-271-5841 | |
Dr. Ekaterina Halivelakis, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6211 | |
Dr. Deborah A. Poplawsky, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6298 | |
Kajal Angras, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 100 North Academy Ave, Danville, PA 17822 Phone: 570-271-6298 Fax: 570-271-5841 |